Stock Events

Stock Events

Decoy Therapeutics 

$1.9900
44
-$0.11-5.24% 05:30 Today

Statistics

Day High
1.99
Day Low
1.92
52W High
9.71
52W Low
1.92
Volume
644
Avg. Volume
-
Mkt Cap
1.3M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12NovExpected
Q3 2025
Q1 2026
Q2 2026
Next
-403.2
-269.66
-136.13
-2.59
Expected EPS
-2.59
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-12.52MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.66B
BioMarin Pharmaceutical develops and commercializes innovative therapies for rare genetic diseases, overlapping with Salarius' focus on rare cancers.
CRISPR Therapeutics
CRSP
Mkt Cap5.24B
CRISPR Therapeutics is involved in gene editing, a cutting-edge technology that could address cancer in ways competitive to Salarius' approach.
Novartis
NVS
Mkt Cap276.48B
Novartis offers a broad portfolio of oncology drugs, directly competing with Salarius Pharmaceuticals in the cancer treatment market.
Gilead Sciences
GILD
Mkt Cap187.15B
Gilead Sciences has a strong presence in oncology and cell therapy, areas that Salarius is also targeting.
AMGEN
AMGN
Mkt Cap224.15B
Amgen has a diverse oncology portfolio, including treatments for rare cancers, making it a direct competitor.
Pfizer
PFE
Mkt Cap163.41B
Pfizer has a large and expanding oncology division, competing across a range of cancer treatments, including those for rare cancers.
Merck
MRK
Mkt Cap367.07B
Merck is known for its cancer treatments, including immunotherapies that compete with Salarius' therapeutic approaches.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.13B
Regeneron Pharmaceuticals, with its focus on innovative biologics for cancer treatment, competes in the same biopharmaceutical space as Salarius.

About

Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise-associated muscle cramps in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which completed an exploratory Phase II clinical trial in Australia for the treatment of patients with multiple sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT products online through its direct-to-consumer Website and through third-party Websites, including a retailer that offers international shipping. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.
Show more...
CEO
ISIN
US79400X5032

Listings

STU
DE
FP11.STU
MU
DE
FP11.MU
XNAS
US
DCOY
BOATS
BOATS
DCOY.BOATS

0 Comments

Share your thoughts

FAQ

What is Decoy Therapeutics stock price today?▼
The current price of DCOY.BOATS is $1.99 USD — it has decreased by -5.24% in the past 24 hours. Watch Decoy Therapeutics stock price performance more closely on the chart.
What is Decoy Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Decoy Therapeutics stocks are traded under the ticker DCOY.BOATS.
What is Decoy Therapeutics market cap?▼
Today Decoy Therapeutics has the market capitalization of 1.3M
When is the next Decoy Therapeutics earnings date?▼
Decoy Therapeutics is going to release the next earnings report on November 12, 2026.
What were Decoy Therapeutics earnings last quarter?▼
DCOY.BOATS earnings for the last quarter are -4.46 USD per share, whereas the estimation was -2.88 USD resulting in a -54.6% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Decoy Therapeutics revenue for the last year?▼
Decoy Therapeutics revenue for the last year amounts to 0 USD.
What is Decoy Therapeutics net income for the last year?▼
DCOY.BOATS net income for the last year is -12.52M USD.
In which sector is Decoy Therapeutics located?▼
Decoy Therapeutics operates in the Other sector.
When did Decoy Therapeutics complete a stock split?▼
The last stock split for Decoy Therapeutics was on March 09, 2026 with a ratio of 1:12.